Long-Acting HIV Treatment and Prevention Project

Injectable HIV regimens may soon supercede once-daily oral pills as the most accessible treatment option, considering that these regimens require far less dosing. In addition, while PrEP has been available for about a decade now in a pill form but recently the FDA has approved a long-acting extended-release injectable, Apretude (cabotegravir).

However, questions remain about the breadth and depth of awareness and potential uptake barriers related to these long-acting products among individuals who may want to consider them.

As part of its Infectious Diseases Initiative, the O’Neill Institute for National and Global Health Law announced a new Long-Acting HIV Treatment and Prevention Policy Project. Made possible by grants from Gilead Sciences, Merck and Company, and ViiV Healthcare, the project will rely on community stakeholders and policymakers, including in this advisory group Damián Cabrera-Candelaria, NMAC; Kenyon Farrow, PrEP4ALL; Tim Horn, NASTAD; Vanessa Johnson, Positive Women’s Network – USA; Antoinette Jones, SisterLove, Inc.; Oscar Lopez, Poderosos; J. Maurice McCants-Pearsall, Human Rights Campaign; Jim Pickett, AIDS Foundation Chicago; and Bamby Salcedo, [email protected] Coalition. The project will build on work already done in partnership with amfAR in 2018.

“Maintaining regular community engagement around long-acting HIV treatment and prevention is important. I am particularly excited that this project will enable us to establish community stakeholder working groups with whom we will create a two-way dialogue to educate communities about emerging products and research findings and identify questions and policy issues to be addressed,” said Sean E. Bland, senior HIV associate and project lead, in a prepared release.